The share price of Suven Life Sciences Ltd. has increased by 130.08% in last one year, while the benchmark index S&P BSE Sensex has increased by 45.71%.
The stock rallied on heavy volumes after the company intimated the exchange on 2nd August 2021 for a Board Meeting which is going to be held on Monday, 9th August 2021.
The meeting will be held for considering and approving the Company’s Unaudited Financial Results (Standalone and Consolidated) for the quarter ended 30th June, 2021, as well as related matters.
In Q4 FY21, the company had reported a consolidated net loss of Rs 21.69 crore, compared to a net loss of Rs 25.74 crore in Q4 FY20.
On a consolidated basis, the company had reported a net loss of Rs 72.45 crore for the fiscal year ended March 31, 2021, compared to a net loss of Rs 94.51 crore for the fiscal year ended March 31, 2020.
Suven Life Sciences is a biopharmaceutical company focused on drug discovery and development of new chemical entities (NCEs) in central nervous system (CNS) disorders with unmet medical needs around the world.
The company was promoted by Mrs. and Mr. Venkat Jasti in 1989, as a Private Limited Company which was later converted into a Public Limited Company in Jan 1995.
Disclaimer: This document and the process of identifying the potential of a company have been produced for only learning purposes. Since equity involves individual judgments, this analysis should be used for only learning enhancements and cannot be considered to be a recommendation on any stock or sector.